Pfizer's Lorbrena breaks into front-line ALK lung cancer, jostling with Novartis, Roche and Takeda

Retrieved on: 2021-03-04 15:45:00

Tags for this article:

Click the tags to see associated articles and topics

Pfizer's Lorbrena breaks into front-line ALK lung cancer, jostling with Novartis, Roche and Takeda. View article details on hiswai:

Excerpt

Roche's Alecensa cut that same risk by 50% in its phase 3 Alex trial, while Takeda's Alunbrig performed similarly with a 51% reduction in its own ...

Article found on: www.fiercepharma.com